Xanthine compounds having a positive allosteric GABAB receptor modulator effect

Details for Australian Patent Application No. 2008241604 (hide)

Owner Astrazeneca AB

Inventors Cheng, Leifeng; Holmqvist, Sara; Raubacher, Florian; Schell, Peter

Agent Freehills

Pub. Number AU-A-2008241604

PCT Pub. Number WO2008/130314

Priority 60/912,533 18.04.07 US; 60/940,474 29.05.07 US

Filing date 17 April 2008

Wipo publication date 30 October 2008

International Classifications

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

A61K 31/522 (2006.01)

A61P 1/04 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

Event Publications

22 October 2009 PCT application entered the National Phase

  PCT publication WO2008/130314 Priority application(s): WO2008/130314

23 August 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008241607-Grinding holder in a machining device

2008241602-A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)p yridin-2-yl]1H-indole-5-carbonitrile 701